OncoMatch/Clinical Trials/NCT06901817
A Study of the Safety and Efficacy of Pemetrexed Combined with Nivolumab Via Intraventricular Injection for the Treatment of Refractory Non-squamous Non-small Cell Lung Cancer with Leptomeningeal Metastases
Is NCT06901817 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Intraventricular Pemetrexed and Intraventricular Nivolumab for leptomeningeal metastasis.
Treatment: Intraventricular Pemetrexed · Intraventricular Nivolumab · Intraventricular Dexamethasone — The goal of this clinical trial is to learn if the intraventricular injection of Pemetrexed and Nivolumab works to treat refractory non-squamous non-small cell lung cancer with leptomeningeal metastases. The main questions to answer are: * Is the combination of Pemetrexed and Nivolumab safe to inject? * How effective is the combination in disease control? Participants will： * Intrathecal injection of 30 mg pemetrexed via Ommaya reservoir, once every 4 weeks until disease progression; * Intrathecal injection of 40 mg nivolumab via Ommaya reservoir, once every 4 weeks until disease progression; * Before each intrathecal administration, a preliminary intrathecal injection of dexamethasone, 5 mg/2 mL, is given.
Check if I qualifyExtracted eligibility criteria
Biomarker criteria
Required: EGFR T790M
Failed first- or second-generation TKI treatment, T790M mutation-negative
Required: EGFR mutation-negative
EGFR gene mutation-negative, failed first-line treatment
Disease stage
Metastatic disease required
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Lab requirements
Blood counts
Kidney function
Liver function
Cardiac function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify